Molecular Templates Announces First Patient Dosed in Phase 1

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Texas , United States , Eric Poma , Molecular Templates Inc , Nasdaq , Exchange Commission , Antigen Seeding Technology , Templates Announces First Patient Dosed , Novel Engineered Toxin Body Targeting , Advanced Solid , Microsatellite Instability High , Mismatch Repair Deficient , Chief Executive , Chief Scientific Officer , Shiga Like Toxin , Private Securities Litigation Reform Act , Molecular Templates , Safe Harbor , Molecular Template , Quarterly Report ,